Pasireotide and octreotide in the treatment of severe late dumping syndrome
نویسندگان
چکیده
Hypoglycemia due to late dumping is a significant problem postoesophagectomy but may not always be diagnosed sufficiently early. It can be difficult to treat and may severely compromise quality of life. The combination of diazoxide and octreotide or more probably pasireotide may transform the patient's life and should be considered in all problematic cases.
منابع مشابه
Therapeutic value of octreotide for patients with severe dumping syndrome--a review of randomised controlled trials.
Approximately 10%–50% of patients develop some manifestations of the dumping syndrome after gastric surgery. Among them, 5%–10% have clinically significant symptoms, and 1%–2% are debilitated by them. Early dumping, typically starting 10–30 minutes after a meal, usually involves both vasomotor and gastrointestinal complaints such as sweating, palpitation, weakness and faintness, abdominal bloat...
متن کاملDiazoxide for the treatment of hypoglycaemic dumping syndrome.
Dumping syndrome is a commonly recognized complication after gastric and oesophageal surgery. It is characterized by postprandial early gastrointestinal and vasomotor symptoms followed by late hypoglycaemia. Early dumping symptoms include abdominal pain, bloating, nausea, vomiting, flushing, tachycardia and hypotension. Late dumping symptoms which occur 1–3 h after food are thought to be due to...
متن کاملPasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst(1,2,3)) and sst(5). Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study ...
متن کاملPasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing's disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide in vitro on meningioma primary cell cultures, both alone a...
متن کاملSomatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteris...
متن کامل